Pharmaceutical - Respiratory and Pulmonary, Rare diseases

Filter

Popular Filters

Zambon to acquire UK respiratory specialist Profile Pharma

10-06-2013

Family-owned Italian drugmaker Zambon has taken a significant step to grow in the respiratory therapy…

Mergers & AcquisitionsPharmaceuticalProfile PharmaPromixinRare diseasesRespiratory and PulmonaryZambon

US FDA calls for new trial with Pharmaxis' CF drug Bronchitol

19-03-2013

Australian pharma company Pharmaxis (ASX: PXS) says it has received a complete response letter from the…

BronchitolNorth AmericaPharmaceuticalPharmaxisRare diseasesRegulationRespiratory and Pulmonary

Cornerstone Thera gets US rights to Chiesi's Bethkis

11-11-2012

USA-based specialty pharma firm Cornerstone Therapeutics Inc. (Nasdaq: CRTX) says it has entered into…

BethkisChiesi FarmaceuticiCornerstone TherapeuticsGenericsLicensingNorth AmericaPharmaceuticalRare diseasesRespiratory and Pulmonary

Canadian scientists' insights into Kalydeco for a rare form of cystic fibrosis

29-10-2012

Scientists at the Hospital for Sick Children in Toronto, Canada, have established that a drug recently…

KalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertexVX-770

UK's NICE reverses earlier negative decision on Pharmaxis' CF treatment Bronchitol

28-10-2012

Australia's Pharmaxis (ASX: PXS) says that the UK drugs watchdog the National Institute for Health and…

BronchitolEuropePharmaceuticalPharmaxisRare diseasesRegulationRespiratory and Pulmonary

Denmark sees first launches of Almirall's Eklira Genuair and ViroPharma's Plenadren

21-09-2012

Spain's largest drugmaker, Almirall (ALM: MC), says that the Danish Health and Medicines Authority has…

AlmirallEklira GenuairEuropeMarkets & MarketingPharmaceuticalPlenadrenRare diseasesRespiratory and PulmonaryViroPharma

Vertex tumbles despite good final data on combo cystic fibrosis therapy

01-07-2012

USA-based Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares tumble 16% to $51.18 last week, after…

KalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertexVX-809

NICE now backs Xarelto to treat blood clots; negative on Bronchitol for CF

01-06-2012

In final draft guidance published today (1 June 1), UK drugs watchdog the National Institute for Health…

BayerBronchitolCardio-vascularEuropePharmaceuticalPharmaxisPricingRare diseasesRegulationRespiratory and PulmonaryXarelto

Vertex slumps as firm revises Kalydeco data

30-05-2012

The USA's Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares plunge 19% to $52.85 in early trading…

KalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertex

EMA recommends approval of Vertex' CF drug Kalydeco

28-05-2012

European Medicines Agency last Friday recommended approval of Kalydeco (ivacaftor), an orphan-designated…

EuropeKalydecoPharmaceuticalRare diseasesRegulationRespiratory and PulmonaryVertex

Vertex’ Kalydeco marks a milestone in fight against cystic fibrosis

06-11-2011

The oral drug ivacaftor (VX-770) provides major, sustained improvement in lung function, growth and other…

ivacaftorKalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertex

UK NICE negative on Sanofi’s Jevtana and GSK’s Benlysta but positive on ALK-Abello’s Pharmalgen

30-09-2011

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) this morning issued…

Alk-AbelloBenlystaEuropeGlaxoSmithKlineJevtanaOncologyPharmaceuticalPharmalgenPricingRare diseasesRegulationRespiratory and PulmonarySanofi

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top